ONI BioPharma Inc. Launches the ProBiora3(TM) Website
2008年9月27日 - 4:38AM
Marketwired
ONI BioPharma Inc. (AMEX: ONI) announced today that it has launched
the official ProBiora3 website at www.probiora3.com. This
business-to-business website is directed at large mass
merchandisers and companies seeking private label products
containing the Company's ProBiora3 ingredient, an all natural
probiotic blend for oral health. ONI BioPharma's first
direct-to-consumer sales website for its own EvoraPlus(TM) oral
care product is expected to be launched shortly under the domain
name www.evoraplus.com. The Company anticipates that the EvoraPlus
website will be the first of several planned direct-to-consumer
sales sites for a group of oral care products manufactured by and
for ONI containing the Company's probiotic ingredient, ProBiora3.
About ONI BioPharma Inc.
ONI BioPharma Inc. is a biopharmaceutical company with a
pipeline of unique proprietary technologies, some of which are
being commercialized. The Company also has a number of products in
discovery, preclinical and clinical development, with a
concentration in the main therapeutic area of infectious diseases,
diagnostics, and oral health. The Company has developed platform
technologies with respect to its products, thereby creating a
pipeline of future products, which the Company expects to
develop.
Safe Harbor Statement: Under the Private Securities Litigation
Reform Act of 1995: This release includes forward-looking
statements that reflect ONI BioPharma's current views with respect
to future events and financial performance. These forward-looking
statements are based on management's beliefs and assumptions and
information currently available. The words "believe," "expect,"
"anticipate," "intend," "estimate," "project" and similar
expressions that do not relate solely to historical matters
identify forward-looking statements. Investors should be cautious
in relying on forward-looking statements because they are subject
to a variety of risks, uncertainties, and other factors that could
cause actual results to differ materially from those expressed in
any such forward-looking statements. These factors include, but are
not limited to those set forth in our most recently filed annual
report on Form 10-KSB and quarterly report on Form 10-Q, and other
factors detailed from time to time in filings with the Securities
and Exchange Commission. We expressly disclaim any responsibility
to update forward-looking statements.
Contact: ONI BioPharma Inc. Stanley B. Stein 386-418-4018 X222
www.oragenics.com
Oragenics (AMEX:ONI)
過去 株価チャート
から 8 2024 まで 9 2024
Oragenics (AMEX:ONI)
過去 株価チャート
から 9 2023 まで 9 2024
Real-Time news about Oragenics, (アメリカ証券取引所): 0 recent articles
その他のOragenics, Inc.ニュース記事